

Attn: Jen Laws PO Box 3009 Slidell, LA 70459

Chief Executive Officer:

Jen Laws Phone: (313) 333-8534 Fax: (646) 786-3825 Email: jen@tiicann.org

Board of Directors:

Kathie Hiers, Chair Darnell Lewis, Secretary

Michelle Anderson Hon. Donna Christensen, MD Dusty Garner Riley Johnson Judith Montenegro Trelvis D. Randolph, Esq Cindy Snyder

Director Emeritus:

William E. Arnold (*in Memoriam*) Jeff Coudriet (*in Memoriam*) Hon. Maurice Hinchey, MC (*in Memoriam*) Gary R. Rose, JD (*in Memoriam*)

National Programs:

340B Action Center

HIV/HCV Co-Infection Watch

Hepatitis Education, Advocacy & Leadership (HEAL) Group

Industry Advisory Group (IAG)

National ADAP Working Group (NAWG)

Community Access National Network Submits Public Comment to Senator's Bipartisan 340B Working Group

Request for Information Seeks Input on Needed Reforms

WASHINGTON, DC (July 27, 2023) – The Community Access National Network, otherwise known as CANN, in collaboration with ADAP Advocacy submitted public comment in response to the <u>Request for Information</u> (RFI) issued by the Senator's Bipartisan 340B Working Group seeking feedback on the 340B Drug Pricing Program. CANN is deeply committed to the success of the 340B Program, which dates to 1992 when Congress struck a deal with pharmaceutical manufacturers to expand access to care and medication for more patients.

The working group is comprised of the following U.S. Senators: John Thune (R-S.D.), Debbie Stabenow (D-Mich.), Shelley Moore Capito (R-W.Va.), Tammy Baldwin (D-Wis.), Jerry Moran (R-Kan.), and Ben Cardin (D-Md.). The RFI seeks "input on bipartisan policy solutions that would provide stability and appropriate transparency to ensure the 340B program can continue to achieve its original intent of supporting entities serving eligible patients."

Summarized Jen Laws, CANN President & CEO: "The RFI from Senators is a welcomed opportunity to revisit the intent of 340B – which is to 'stretch scarce federal resources' in serving needy patients and communities. We can and do recognize different stakeholders find different ways to do that. But the lack of transparency stakeholders currently enjoy means we don't know who is benefitting and how. In an environment of consolidation and increased medical debt, these very serious concerns need to be addressed with meaningful, patient-drive policy change."

CANN's leadership on 340B dates to 2018, when the organization appointed a national commission to take a thorough and candid review of the program. The commission made <u>specific recommendations</u> to Congress on how and in what ways the program should be strengthened.

Community Access National Network Submits Public Comment to Senator's Bipartisan 340B Working Group July 27, 2023

Riley Johnson, CANN Board Member and member of the ADAP Advocacy's <u>Ryan White Grantee 340B Patient Advisory Committee</u>, said: "The importance of the 340B Program cannot be emphasized enough, especially for services under the Ryan White HIV/AIDS Program, but it does beg the question why aren't patients, like myself, benefitting more directly from the program. For example, grantees provide healthcare services on a sliding scale basis, but those requirements do not extend to their contract pharmacies."

CANN's public comments on the 340B RFI can be read online at <u>http://tiicann.org/public-comments.html</u>.

To view CANN's advocacy and educational work on the 340B Drug Pricing Program, visit <u>https://www.tiicann.org/340b_action-center.html</u>.

For general information, please contact CANN at <u>info@tiicann.org</u>.

####

About the Community Access National Network: The mission of the Community Access National Network (CANN) is to define, promote, and improve access to healthcare services and supports for people living with HIV/AIDS and/or Viral Hepatitis through advocacy, education, and networking. These services must be affordable to the people who need them regardless of insurance status, income, or geographic location.